

sven Francque

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5997573/sven-francque-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

129
papers

7,108
citations

44
h-index

83
g-index

142
ext. papers

9,695
ext. citations

6.8
avg, IF

5.9
L-index

#	Paper	IF	Citations
129	Vasoconstrictor antagonism improves functional and structural vascular alterations and liver damage in rats with early NAFLD.. <i>JHEP Reports</i> , 2022 , 4, 100412	10.3	1
128	Breakthroughs in therapies for NASH and remaining challenges.. <i>Journal of Hepatology</i> , 2022 , 76, 1263-1278	13.4	1
127	Macrophage Scavenger Receptor 1 mediates lipid-induced inflammation in non-alcoholic fatty liver disease.. <i>Journal of Hepatology</i> , 2021 ,	13.4	4
126	NAFLD in type 1 diabetes: overrated or underappreciated?. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2021 , 12, 20420188211055557	4.5	1
125	Hepatopathy Associated With Type 1 Diabetes: Distinguishing Non-alcoholic Fatty Liver Disease From Glycogenic Hepatopathy. <i>Frontiers in Pharmacology</i> , 2021 , 12, 768576	5.6	3
124	Decompensation in Advanced Nonalcoholic Fatty Liver Disease May Occur at Lower Hepatic Venous Pressure Gradient Levels Than in Patients With Viral Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2021 ,	6.9	11
123	A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH. <i>New England Journal of Medicine</i> , 2021 , 385, 1547-1558	59.2	50
122	Advancing the global public health agenda for NAFLD: a consensus statement. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021 ,	24.2	37
121	NAFLD in lean individuals: not a benign disease. <i>Gut</i> , 2021 ,	19.2	4
120	Liver Fibrosis in Non-alcoholic Fatty Liver Disease: From Liver Biopsy to Non-invasive Biomarkers in Diagnosis and Treatment. <i>Frontiers in Medicine</i> , 2021 , 8, 615978	4.9	21
119	Sorted B cell transcriptomes point towards actively regulated B cell responses during ongoing chronic hepatitis B infections. <i>Cellular Immunology</i> , 2021 , 362, 104283	4.4	3
118	The Effect of a Novel Serine Protease Inhibitor on Inflammation and Intestinal Permeability in a Murine Colitis Transfer Model. <i>Frontiers in Pharmacology</i> , 2021 , 12, 682065	5.6	1
117	Hepatic Molecular Signatures Highlight the Sexual Dimorphism of Nonalcoholic Steatohepatitis (NASH). <i>Hepatology</i> , 2021 , 73, 920-936	11.2	15
116	Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021 , 18, 24-39	24.2	67
115	PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis. <i>Journal of Hepatology</i> , 2021 , 74, 1097-1108	13.4	41
114	NASH-related increases in plasma bile acid levels depend on insulin resistance. <i>JHEP Reports</i> , 2021 , 3, 100222	10.3	9
113	Therapeutic approaches for non-alcoholic steatohepatitis. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2021 , 12, 20420188211034300	4.5	1

112	Two-dimensional shear wave elastography predicts survival in advanced chronic liver disease. <i>Gut</i> , 2021 ,	19.2	16
111	A targeted multi-omics approach reveals paraoxonase-1 as a determinant of obesity-associated fatty liver disease. <i>Clinical Epigenetics</i> , 2021 , 13, 158	7.7	3
110	Muscle fat content is strongly associated with NASH: A longitudinal study in patients with morbid obesity. <i>Journal of Hepatology</i> , 2021 , 75, 292-301	13.4	13
109	Reply to: "Intermuscular abdominal fat fraction and metabolic dysfunction-associated fatty liver disease: Does the link already exist in childhood?". <i>Journal of Hepatology</i> , 2021 , 75, 1513-1514	13.4	
108	Non-alcoholic fatty liver disease: A patient guideline. <i>JHEP Reports</i> , 2021 , 3, 100322	10.3	17
107	Diet Reversal and Immune Modulation Show Key Role for Liver and Adipose Tissue T Cells in Murine Nonalcoholic Steatohepatitis. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2020 , 10, 467-490	7.9	9
106	A pharmacokinetic study to guide dosing of tenofovir disoproxil fumarate during different modalities of renal replacement therapy. <i>Clinical Biochemistry</i> , 2020 , 83, 86-88	3.5	
105	Cenicriviroc Treatment for Adults With Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study. <i>Hepatology</i> , 2020 , 72, 892-905	11.2	116
104	Standardisation of diet and exercise in clinical trials of NAFLD-NASH: Recommendations from the Liver Forum. <i>Journal of Hepatology</i> , 2020 , 73, 680-693	13.4	32
103	A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial. <i>Contemporary Clinical Trials</i> , 2020 , 88, 105889	2.3	45
102	The European NAFLD Registry: A real-world longitudinal cohort study of nonalcoholic fatty liver disease. <i>Contemporary Clinical Trials</i> , 2020 , 98, 106175	2.3	28
101	The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology. <i>Journal of Hepatology</i> , 2020 , 73, 842-854	13.4	108
100	Non-Alcoholic Steatohepatitis Decreases Microsomal Liver Function in the Absence of Fibrosis. <i>Biomedicines</i> , 2020 , 8,	4.8	1
99	A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study. <i>The Lancet Gastroenterology and Hepatology</i> , 2020 , 5, 970-985	18.8	54
98	Adoptive Cell Transfer of Regulatory T Cells Exacerbates Hepatic Steatosis in High-Fat High-Fructose Diet-Fed Mice. <i>Frontiers in Immunology</i> , 2020 , 11, 1711	8.4	7
97	Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort. <i>Journal of Hepatology</i> , 2020 , 73, 505-515	13.4	113
96	Plasma BCAA Changes in Patients With NAFLD Are Sex Dependent. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020 , 105,	5.6	16
95	Transcriptional Network Analysis Implicates Altered Hepatic Immune Function in NASH development and resolution. <i>Nature Metabolism</i> , 2019 , 1, 604-614	14.6	48

94	Portal Hypertension in NASH: Is It Different from Other Aetiologies?. <i>Current Hepatology Reports</i> , 2019 , 18, 134-143	1	
93	Pharmacological Treatment for Non-alcoholic Fatty Liver Disease. <i>Advances in Therapy</i> , 2019 , 36, 1052-1074	17.4	37
92	Targeting Myeloid-Derived Cells: New Frontiers in the Treatment of Non-alcoholic and Alcoholic Liver Disease. <i>Frontiers in Immunology</i> , 2019 , 10, 563	8.4	14
91	Hepatocyte-specific loss of GPS2 in mice reduces non-alcoholic steatohepatitis via activation of PPAR α . <i>Nature Communications</i> , 2019 , 10, 1684	17.4	27
90	The Differential Roles of T Cells in Non-alcoholic Fatty Liver Disease and Obesity. <i>Frontiers in Immunology</i> , 2019 , 10, 82	8.4	86
89	Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity. <i>Alimentary Pharmacology and Therapeutics</i> , 2019 , 50, 193-203	6.1	62
88	Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. <i>Lancet, The</i> , 2019 , 394, 2184-2196	40	425
87	Sarcopenia in patients with non-alcoholic fatty liver disease: is it a clinically significant entity?. <i>Obesity Reviews</i> , 2019 , 20, 353-363	10.6	22
86	The potential role of vascular alterations and subsequent impaired liver blood flow and hepatic hypoxia in the pathophysiology of non-alcoholic steatohepatitis. <i>Medical Hypotheses</i> , 2019 , 122, 188-197 ^{3.8}	3.8	18
85	Severe steatosis induces portal hypertension by systemic arterial hyporeactivity and hepatic vasoconstrictor hyperreactivity in rats. <i>Laboratory Investigation</i> , 2018 , 98, 1263-1275	5.9	22
84	Assessment of biopsy-proven liver fibrosis by two-dimensional shear wave elastography: An individual patient data-based meta-analysis. <i>Hepatology</i> , 2018 , 67, 260-272	11.2	213
83	A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis. <i>Hepatology</i> , 2018 , 67, 1754-1767	11.2	376
82	Circulating PCSK9 levels are not associated with the severity of hepatic steatosis and NASH in a high-risk population. <i>Atherosclerosis</i> , 2018 , 278, 82-90	3.1	17
81	Identifying Therapeutic Targets for Sepsis Research: A Characterization Study of the Inflammatory Players in the Cecal Ligation and Puncture Model. <i>Mediators of Inflammation</i> , 2018 , 2018, 5130463	4.3	9
80	Measuring future liver remnant function prior to hepatectomy may guide the indication for portal vein occlusion and avoid posthepatectomy liver failure: a prospective interventional study. <i>Hpb</i> , 2017 , 19, 108-117	3.8	14
79	A stepwise algorithm using an at-a-glance first-line test for the non-invasive diagnosis of advanced liver fibrosis and cirrhosis. <i>Journal of Hepatology</i> , 2017 , 66, 1158-1165	13.4	56
78	Sequential shear-wave elastography of liver and spleen rules out clinically significant portal hypertension in compensated advanced chronic liver disease. <i>Gut</i> , 2017 , 66, 558-559	19.2	10
77	Efficacy, safety and pharmacokinetics of simeprevir and TMC647055/ritonavir with or without ribavirin and JNJ-56914845 in HCV genotype 1 infection. <i>BMC Gastroenterology</i> , 2017 , 17, 26	3	4

76	The new-generation pan-peroxisome proliferator-activated receptor agonist IVA337 protects the liver from metabolic disorders and fibrosis. <i>Hepatology Communications</i> , 2017 , 1, 524-537	6	66
75	A cross-sectional study of hepatitis C among people living with HIV in Cambodia: Prevalence, risk factors, and potential for targeted screening. <i>PLoS ONE</i> , 2017 , 12, e0183530	3.7	19
74	Prediction of presence of oesophageal varices just by shear-wave elastography of the liver and spleen. <i>Liver International</i> , 2017 , 37, 1406-1407	7.9	1
73	Bile Acid Alterations Are Associated With Insulin Resistance, but Not With NASH, in Obese Subjects. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017 , 102, 3783-3794	5.6	55
72	Shear-wave elastography of the liver and spleen identifies clinically significant portal hypertension: A prospective multicentre study. <i>Liver International</i> , 2017 , 37, 396-405	7.9	90
71	Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis. <i>American Journal of Gastroenterology</i> , 2017 , 112, 740-751	0.7	273
70	Interspecies NASH disease activity whole-genome profiling identifies a fibrogenic role of PPAR β -regulated dermatopontin. <i>JCI Insight</i> , 2017 , 2,	9.9	53
69	Animal Models of Nonalcoholic Fatty Liver Disease-A Starter's Guide. <i>Nutrients</i> , 2017 , 9,	6.7	153
68	Peripheral Venous, Portal Venous, Hepatic Venous, and Arterial and Intrahepatic Cytokine Levels as Biomarkers and Functional Correlations. <i>Biomarkers in Disease</i> , 2017 , 581-602		0
67	Innovative molecular targeted agents in hepatocellular carcinoma: new gladiators on the arena. <i>Minerva Surgery</i> , 2017 , 72, 206-218	0.1	
66	Hepatocellular autophagy modulates the unfolded protein response and fasting-induced steatosis in mice. <i>American Journal of Physiology - Renal Physiology</i> , 2016 , 311, G599-G609	5.1	27
65	In Vitro Recording of Mesenteric Afferent Nerve Activity in Mouse Jejunal and Colonic Segments. <i>Journal of Visualized Experiments</i> , 2016 ,	1.6	4
64	Non-alcoholic fatty liver disease and cardiovascular risk: Pathophysiological mechanisms and implications. <i>Journal of Hepatology</i> , 2016 , 65, 425-43	13.4	239
63	Noninvasive Detection of Nonalcoholic Steatohepatitis Using 'Clinical Markers and Circulating Levels of Lipids and 'Metabolites. <i>Clinical Gastroenterology and Hepatology</i> , 2016 , 14, 1463-1472.e6	6.9	82
62	Future remnant liver function estimated by combining liver volumetry on magnetic resonance imaging with total liver function on (99m)Tc-mebrofenin hepatobiliary scintigraphy: can this tool predict post-hepatectomy liver failure?. <i>Hpb</i> , 2016 , 18, 494-503	3.8	60
61	Liver Fibrosis Evaluation Using Real-time Shear Wave Elastography in Hepatitis C-Monoinfected and Human Immunodeficiency Virus/Hepatitis C-Coinfected Patients. <i>Journal of Ultrasound in Medicine</i> , 2016 , 35, 1299-308	2.9	13
60	Screening for rare variants in the PNPLA3 gene in obese liver biopsy patients. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2016 , 40, 715-721	2.4	2
59	Successful antiviral treatment of chronic hepatitis C leads to a rapid decline of liver stiffness without an early effect on spleen stiffness. <i>Hepatology</i> , 2016 , 64, 1809-1810	11.2	19

58	Pathophysiology and Mechanisms of Nonalcoholic Fatty Liver Disease. <i>Annual Review of Physiology</i> , 2016 , 78, 181-205	23.1	212
57	Algorithm to rule out clinically significant portal hypertension combining Shear-wave elastography of liver and spleen: a prospective multicentre study. <i>Gut</i> , 2016 , 65, 1057-8	19.2	43
56	Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor- α Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening. <i>Gastroenterology</i> , 2016 , 150, 1147-1159.e5	13.3	629
55	Intensive Enteral Nutrition Is Ineffective for Patients With Severe Alcoholic Hepatitis Treated With Corticosteroids. <i>Gastroenterology</i> , 2016 , 150, 903-10.e8	13.3	86
54	Association study of PNPLA2 gene with histological parameters of NAFLD in an obese population. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2016 , 40, 333-339	2.4	5
53	Peripheral Venous, Portal Venous, Hepatic Venous, and Arterial and Intrahepatic Cytokine Levels as Biomarkers and Functional Correlations. <i>Exposure and Health</i> , 2016 , 1-22	8.8	
52	Pro-Inflammatory Cytokines but Not Endotoxin-Related Parameters Associate with Disease Severity in Patients with NAFLD. <i>PLoS ONE</i> , 2016 , 11, e0166048	3.7	40
51	Beneficial Effects of Anti-Interleukin-6 Antibodies on Impaired Gastrointestinal Motility, Inflammation and Increased Colonic Permeability in a Murine Model of Sepsis Are Most Pronounced When Administered in a Preventive Setup. <i>PLoS ONE</i> , 2016 , 11, e0152914	3.7	15
50	Autophagy in Non-Alcoholic Fatty Liver Disease (NAFLD) 2016 ,		1
49	EFFECT OF GTS-21, AN ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONIST, ON CLP-INDUCED INFLAMMATORY, GASTROINTESTINAL MOTILITY, AND COLONIC PERMEABILITY CHANGES IN MICE. <i>Shock</i> , 2016 , 45, 450-9	3.4	22
48	Alcohol intake increases the risk of HCC in hepatitis C virus-related compensated cirrhosis: A prospective study. <i>Journal of Hepatology</i> , 2016 , 65, 543-51	13.4	50
47	Efficacy and safety of simeprevir with PegIFN/ribavirin in naïve or experienced patients infected with chronic HCV genotype 4. <i>Journal of Hepatology</i> , 2015 , 62, 1047-55	13.4	64
46	PPAR α gene expression correlates with severity and histological treatment response in patients with non-alcoholic steatohepatitis. <i>Journal of Hepatology</i> , 2015 , 63, 164-73	13.4	178
45	Mechanisms contributing to visceral hypersensitivity: focus on splanchnic afferent nerve signaling. <i>Neurogastroenterology and Motility</i> , 2015 , 27, 1709-20	4	9
44	Peripheral and Hepatic Vein Cytokine Levels in Correlation with Non-Alcoholic Fatty Liver Disease (NAFLD)-Related Metabolic, Histological, and Haemodynamic Features. <i>PLoS ONE</i> , 2015 , 10, e0143380	3.7	43
43	CD4 ⁺ ROR γ ⁺ and Tregs in a Mouse Model of Diet-Induced Nonalcoholic Steatohepatitis. <i>Mediators of Inflammation</i> , 2015 , 2015, 239623	4.3	19
42	Association of Adipose Tissue Inflammation With Histologic Severity of Nonalcoholic Fatty Liver Disease. <i>Gastroenterology</i> , 2015 , 149, 635-48.e14	13.3	179
41	Cross talk of the immune system in the adipose tissue and the liver in non-alcoholic steatohepatitis: Pathology and beyond. <i>World Journal of Hepatology</i> , 2015 , 7, 1905-12	3.4	16

40	Validation of APRI and FIB-4 score in an Antwerp cohort of chronic hepatitis C patients. <i>Acta Gastro-Enterologica Belgica</i> , 2015 , 78, 373-80	0.6	2
39	SULF2 strongly predisposes to fasting and postprandial triglycerides in patients with obesity and type 2 diabetes mellitus. <i>Obesity</i> , 2014 , 22, 1309-16	8	23
38	TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease. <i>Nature Communications</i> , 2014 , 5, 4309	17.4	362
37	Lack of efficacy of an inhibitor of PDE4 in phase 1 and 2 trials of patients with nonalcoholic steatohepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2014 , 12, 1724-30.e5	6.9	30
36	Prothrombotic factors in histologically proven nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. <i>Hepatology</i> , 2014 , 59, 121-9	11.2	112
35	Diagnostic challenges in alcohol use disorder and alcoholic liver disease. <i>World Journal of Gastroenterology</i> , 2014 , 20, 8024-32	5.6	7
34	Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis. <i>PLoS Medicine</i> , 2014 , 11, e1001680	11.6	363
33	Reply: To PMID 24375485. <i>Hepatology</i> , 2014 , 60, 1451	11.2	
32	The Role of Non-alcoholic Fatty Liver Disease in Cardiovascular Disease. <i>European Cardiology Review</i> , 2014 , 9, 10-15	3.9	6
31	Role of autophagy in the pathophysiology of nonalcoholic fatty liver disease: a controversial issue. <i>World Journal of Gastroenterology</i> , 2014 , 20, 7325-38	5.6	70
30	Prediction of non-alcoholic fatty-liver disease and liver fat content by serum molecular lipids. <i>Diabetologia</i> , 2013 , 56, 2266-74	10.3	100
29	Immunological mechanisms in the pathophysiology of non-alcoholic steatohepatitis. <i>International Journal of Molecular Sciences</i> , 2013 , 14, 19867-90	6.3	50
28	Spontaneous liver bleeding in a patient with congenital arterioportal fistulisation. Presentation of a casus princeps and review of the literature. <i>Acta Gastro-Enterologica Belgica</i> , 2013 , 76, 62-5	0.6	
27	Noninvasive assessment of nonalcoholic fatty liver disease in obese or overweight patients. <i>Clinical Gastroenterology and Hepatology</i> , 2012 , 10, 1162-8; quiz e87	6.9	52
26	Reply to: α -reactive protein levels in non-alcoholic fatty liver disease \square <i>Journal of Hepatology</i> , 2012 , 56, 508-510	13.4	1
25	Evaluation of inflammatory and angiogenic factors in patients with non-alcoholic fatty liver disease. <i>Cytokine</i> , 2012 , 59, 442-9	4	76
24	N-glycan based biomarker distinguishing non-alcoholic steatohepatitis from steatosis independently of fibrosis. <i>Digestive and Liver Disease</i> , 2012 , 44, 315-22	3.3	29
23	Increased intrahepatic resistance in severe steatosis: endothelial dysfunction, vasoconstrictor overproduction and altered microvascular architecture. <i>Laboratory Investigation</i> , 2012 , 92, 1428-39	5.9	72

22	Epidemiology and treatment of autoimmune hepatitis. <i>Hepatic Medicine: Evidence and Research</i> , 2012 , 4, 1-10	3.4	12
21	Update of the Belgian Association for the Study of the Liver guidelines for the treatment of chronic hepatitis C genotype 1 with protease inhibitors. <i>Acta Gastro-Enterologica Belgica</i> , 2012 , 75, 245-59	0.6	3
20	C-reactive protein levels in relation to various features of non-alcoholic fatty liver disease among obese patients. <i>Journal of Hepatology</i> , 2011 , 55, 660-665	13.4	68
19	Visceral adiposity and insulin resistance are independent predictors of the presence of non-cirrhotic NAFLD-related portal hypertension. <i>International Journal of Obesity</i> , 2011 , 35, 270-8	5.5	32
18	Transcriptional activation of apolipoprotein CIII expression by glucose may contribute to diabetic dyslipidemia. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2011 , 31, 513-9	9.4	106
17	High prevalence of advanced fibrosis in association with the metabolic syndrome in a Belgian prospective cohort of NAFLD patients with elevated ALT. Results of the Belgian NAFLD registry. <i>Acta Gastro-Enterologica Belgica</i> , 2011 , 74, 9-16	0.6	5
16	Non-alcoholic steatohepatitis induces non-fibrosis-related portal hypertension associated with splanchnic vasodilation and signs of a hyperdynamic circulation in vitro and in vivo in a rat model. <i>Liver International</i> , 2010 , 30, 365-75	7.9	33
15	Large spectrum of liver vascular lesions including high prevalence of focal nodular hyperplasia in patients with hereditary haemorrhagic telangiectasia: the Belgian Registry based on 30 patients. <i>European Journal of Gastroenterology and Hepatology</i> , 2010 , 22, 1253-9	2.2	41
14	Noncirrhotic human nonalcoholic fatty liver disease induces portal hypertension in relation to the histological degree of steatosis. <i>European Journal of Gastroenterology and Hepatology</i> , 2010 , 22, 1449-57 ²	7.2	44
13	Rapidly evolving liver decompensation with some remarkable features 14 years after biliopancreatic derivation: a case report and literature review. <i>Acta Gastro-Enterologica Belgica</i> , 2010 , 73, 46-51	0.6	4
12	Acute fatty liver of pregnancy and molecular absorbent recirculating system (MARS)-therapy: a case report. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2008 , 21, 587-9	2	13
11	Intestinal bowel perforation and bacterial peritonitis secondary to migrated biliary and pancreatic stents. <i>Endoscopy</i> , 2008 , 40 Suppl 2, E25	3.4	6
10	Fine needle trucut biopsy in focal liver lesions: a reliable and safe method in identifying the malignant nature of liver lesions. <i>Acta Gastro-Enterologica Belgica</i> , 2007 , 70, 1-5	0.6	
9	Viral hepatitis and hepatocellular carcinoma. <i>World Journal of Surgical Oncology</i> , 2005 , 3, 27	3.4	94
8	Bilateral adrenal haemorrhage and acute adrenal insufficiency in a blunt abdominal trauma: a case-report and literature review. <i>European Journal of Emergency Medicine</i> , 2004 , 11, 164-7	2.3	32
7	Multifactorial aetiology of hepatic infarction: a case report with literature review. <i>European Journal of Gastroenterology and Hepatology</i> , 2004 , 16, 411-5	2.2	21
6	Bacillus Calmette-Guérin-induced granulomatous hepatitis in a patient with a superficial bladder carcinoma. <i>European Journal of Gastroenterology and Hepatology</i> , 2004 , 16, 1027-32	2.2	22
5	Coagulation disorders in patients with cirrhosis and severe sepsis. <i>Liver International</i> , 2003 , 23, 440-8	7.9	85

4	Biopsy of focal liver lesions: guidelines, comparison of techniques and cost-analysis. <i>Acta Gastro-Enterologica Belgica</i> , 2003 , 66, 160-5	0.6	4
3	Perforating oesophageal carcinoma presenting as necrotizing fasciitis of the neck. <i>European Journal of Gastroenterology and Hepatology</i> , 2001 , 13, 1261-4	2.2	3
2	Ultrasonically guided fine needle puncture of focal liver lesions. Review and personal experience. <i>Acta Gastro-Enterologica Belgica</i> , 1998 , 61, 158-63	0.6	3
1	Macrophage Scavenger Receptor 1 mediates lipid-induced inflammation in non-alcoholic fatty liver disease		1